US Moves to Turn Most Favored Nation Drug Pricing Policy Into Law

By transitioning the policy from an executive initiative to federal law, a future president could not simply overturn it with an executive order.

Director of Medicare and Deputy Administrator of CMS Chris Klomp speaks after U.S. President Donald Trump announced a deal with Pfizer to sell drugs at lower prices, in the Oval office of the White House in Washington on Sept. 30, 2025. Ken Cedeno/Reuters

The U.S. government has begun talks with pharmaceutical companies to turn President Donald Trump’s Most Favored Nation drug pricing policy into permanent law, Chris Klomp, chief counselor at the Department of Health and Human Services, told reporters on March 19.

“We’re also beginning to read in pharmaceutical ‌companies ⁠to help them understand the nature of the legislative text, to see if they can buy in, if there’s a version we might reach,” Klomp said.